Dupixent Eczema and Blockbuster Drug

Ads
related to: Dupixent Eczema and Blockbuster Drug
DUPIXENT® (dupilumab) - HCPs: View Mechanism Of Action

www.dupixenthcp.com
Official HCP Site— Find Patient Support, Patient Resources, & Safety Information Now. See Dosage Regimen & Administration Information For DUPIXENT® (dupilumab) On The HCP Site
Service catalog: Prescribing Info, Mechanism Of Action, Safety Information
Dosing & Administration
View Dosage Regimen.

Read Administration Instructions.

Getting Started
Learn More About Dosing Schedules

Find Answers To Your Questions

Mechanism Of Action
See How This Treatment Option Works

Watch The Video Today!

View Study Designs
See Clinical Trial Info

Learn More Today!

Support Resources
Access Support For Patients

Download Resources Today

Coverage Support
Learn More About Insurance

Download Guide And Sample Letter
DUPIXENT® (dupilumab) - FDA-Approved Treatment Option

www.dupixent.com
The DUPIXENT® MyWay Copay Card May Help Cover Costs. View Eligibility Requirements Today! Learn More About DUPIXENT® (dupilumab) Rx Treatment. Visit The Official Patient Site Today
Service catalog: Copay Card, Safety Information, Patient Education, Savings Program
FAQs
Home
Getting Started
Sign Up
Patient Support
Treatment Support

Search results

- Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
  Zacks via Yahoo Finance· 1 year ago
  Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...
- Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
  Investor's Business Daily· 5 months ago
  Regeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
- Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
  Zacks via Yahoo Finance· 1 year ago
  This week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a...
- US FDA approves Dupixent to treat younger kids with esophageal condition
  Reuters via AOL· 3 months ago
  (Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to...
- Sanofi forecasts moderate profit growth on Dupixent demand
  Reuters via Yahoo News· 1 year ago
  (Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...
- Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
  Investor's Business Daily· 1 year ago
  Regeneron stock surged Friday on stronger-than-expected metrics, though its partner Sanofi posted a...
- Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall
  Investor's Business Daily· 2 years ago
  Sanofi stock ended flat Thursday — reversing earlier declines — despite lifting its profit guidance...
- ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
  Zacks via Yahoo Finance· 2 months ago
  ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
- Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
  Benzinga via Yahoo Finance· 1 year ago
  French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in...
- Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
  Zacks via Yahoo Finance· 2 years ago
  Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug...